CAR-iNKT cells targeting clonal TCRVβ chains as a precise strategy to treat T cell lymphoma

IntroductionMost T cell receptor (TCR)V beta chain-expressing T cell lymphomas (TCL) including those caused by Human T cell leukaemia virus type-1 (HTLV-1) have poor prognosis. We hypothesised that chimeric antigen receptor (CAR)-mediated targeting of the clonal, lymphoma-associated TCR beta chains would comprise an effective cell therapy for TCL that would minimally impact the physiological TCR repertoire. MethodsAs proof of concept, we generated CAR constructs to target four TCRV beta subunits. Efficacy of the CAR constructs was tested using conventional T cells as effectors (CAR-T). Since invariant NKT (iNKT) cell do not incite acute graft-versus-host disease and are suitable for 'off-the-shelf' immunotherapy, we generated anti-TCRV beta CAR-iNKT cells. ResultsWe show that anti-TCRV beta CAR-T cells selectively kill their cognate tumour targets while leaving >90% of the physiological TCR repertoire intact. CAR-iNKT cells inhibited the growth of TCL in vivo, and were also selectively active against malignant cells from Adult T cell leukaemia/lymphoma patients without activating expression of HTLV-1. DiscussionThus we provide proof-of-concept for effective and selective anti-TCRV beta CAR-T and -iNKT cell-based therapy of TCL with the latter providing the option for 'off-the-shelf' immunotherapy.

Automated summary

This study aimed to validate the effectiveness of chimeric antigen receptor (CAR)-mediated cell therapy targeting specific T cell receptor beta chains in T cell lymphoma (TCL). The experimental results using CAR-T and CAR-iNKT cells demonstrated that this therapy method can selectively kill cancer cells while preserving most of the normal immune function.